However, in vitro studies concluded that the potential estrogen-like properties of promestriene to stimulate the growth of estrogen receptor-reactive breast cancer cell lines, especially under conditions of estrogen deprivation, suggest caution when prescribing for vaginal atrophy in postmenopausal BCS. This evidence concerns the gene ESR1 and breast cancer.